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A B S T R A C T
G-Protein coupled receptors (GPCRs) activate intracellular signalling pathways by coupling to heterotrimeric G-
proteins that control many physiological processes including blood pressure homeostasis. The Regulator of G-
Protein Signalling-1 (RGS1) controls the magnitude and duration of downstream GPCR signalling by acting as a
GTPase-activating protein for speciﬁc Gα-proteins. RGS1 has contrasting roles in haematopoietic and non-
haematopoietic cells. Rgs1−/−ApoE−/− mice are protected from Angiotensin II (Ang II)-induced aortic an-
eurysm rupture. Conversely, Ang II treatment increases systolic blood pressure to a greater extent in Rgs1−/
−ApoE−/− mice than ApoE−/− mice, independent of its role in myeloid cells. However the precise role of RGS1
in hypertension and vascular-derived cells remains unknown. We determined the eﬀects of Rgs1 deletion on
vascular function in ApoE−/− mice. Rgs1 deletion led to enhanced vasoconstriction in aortas and mesenteric
arteries from ApoE−/− mice in response to phenylephrine (PE) and U46619 respectively. Rgs1 was shown to
have a role in the vasculature, with endothelium-dependent vasodilation being impaired, and endothelium-
independent dilatation to SNP being enhanced in Rgs1−/−ApoE−/− mesenteric arteries. To address the down-
stream signalling pathways in vascular smooth muscle cells (VSMCs) in response to Ang II-stimulation, we
assessed pErk1/2, pJNK and pp38 MAPK activation in VSMCs transiently transfected with Rgs1. pErk1/2 sig-
nalling but not pJNK and pp38 signalling was impaired in the presence of Rgs1. Furthermore, we demonstrated
that the enhanced contractile response to PE in Rgs1−/−ApoE−/− aortas was reduced by a MAPK/Erk (MEK)
inhibitor and an L-type voltage gated calcium channel antagonist, suggesting that Erk1/2 signalling and calcium
inﬂux are major eﬀectors of Rgs1-mediated vascular contractile responses, respectively. These ﬁndings indicate
RGS1 is a novel regulator of blood pressure homeostasis and highlight RGS1-controlled signalling pathways in
the vasculature that may be new drug development targets for hypertension.
1. Introduction
Hypertension is a key risk factor for the development of cardio-
vascular diseases that can be associated with increased G protein-cou-
pled receptor (GPCR) signalling. Vasoactive substances that activate
GPCRs can regulate blood pressure homeostasis by eﬀecting vessel tone
acutely. However, longer term changes in systemic pressure and cardiac
output leading to vascular dysfunction can result in clinical complica-
tions, indicating that tight regulation of GPCR signalling pathways is
required to control blood pressure [1]. Many physiologically important
vasoactive substances such as angiotensin II (Ang II), noradrenaline,
acetylcholine (ACh) signal through multiple GPCRs that couple to the
heterotrimeric G-protein families of the Gαq and Gαi subunits [2].
Vascular smooth muscle cells (VSMCs) are responsible for the con-
tractile and dilatory activity of the vessel wall and thereby modulate
peripheral resistance [3]. In SMCs, both Ang II and noradrenaline
mediate vasoconstriction by activation of Gαq coupled receptors. Sig-
nalling by Gαq coupled receptor signalling activates several in-
tracellular pathways including diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3), resulting in activation of protein kinase C (PKC)
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and calcium release from intracellular stores, respectively [4]. Calcium
entry across the plasma membrane and release from intracellular stores
consequently leads to myosin light chain (MLC) phosphorylation, acti-
vation and ultimately vasoconstriction.
Regulator of G-Protein Signalling (RGS) proteins can modulate G-
protein signalling by acting as GTPase-activating proteins (GAPs) by
accelerating the intrinsic GTPase activity of the Gα subunit leading to
reformation and inactivation of the heterotrimer [5]. By promoting G-
protein inactivation, the intracellular response to repeated ligand sti-
mulation is down regulated. We have previously shown that RGS1 has a
critical role in regulating Ang II mediated aortic aneurysm rupture in
ApoE−/− mice through attenuation of Gαi chemokine receptor signal-
ling in leukocytes [6]. Rgs1 expression is up-regulated in activated in-
ﬂammatory cells where it functions to inhibit migration, thus pro-
moting the accumulation of leukocytes during inﬂammation.
Furthermore, there is indication that RGS1 is involved in Ang II-medi-
ated blood pressure control via Gαq signalling, independent of its role
in myeloid cells and aneurysm formation. Other RGS proteins have
been implicated in blood pressure control [1], however, to date, the
role of RGS1 in non-haematopoetic cells and as a regulator of vascular
tone has not been explored. Understanding the mechanisms that un-
derlie G-protein signalling pathways in blood pressure homeostasis may
provide new therapeutic targets for hypertension.
To identify physiological mechanisms by which RGS1 regulates
blood pressure, we investigated the role of Rgs1 in vessel wall activa-
tion, and the eﬀect of Rgs1 deletion on vascular function in the conduit
and resistance vasculature. We used Rgs1−/− mice on an ApoE−/−
background, as hyperlipidemia is a common co-morbidity with hy-
pertension. Our ﬁndings provide the ﬁrst evidence indicating that RGS1
mediates blood pressure by promoting relaxation of the resistance
vasculature through its ability to attenuate vasoconstrictor-induced
signalling.
2. Methods
2.1. Mice
The generation of Rgs1−/− mice has been previously described [7].
Rgs1−/− mice were crossed onto an ApoE−/− background (Charles
River, UK) to generate matched litters of Rgs1−/−ApoE−/− and ApoE−/
− mice. Mice were housed in individually ventilated cages with 12 h
light/dark cycle and controlled temperature (20 °C - 22 °C). Standard
chow (B & K Universal Ltd., UK) and water were available ad libitum.
All animal studies were conducted with ethical approval from the Local
Ethical Review Committee and in accordance with the UK Home Oﬃce
Animals (Scientiﬁc Procedures) Act 1986. For bone marrow trans-
plantation studies, ten-week-old male mice received a lethal dose of
whole-body irradiation (2×5Gy) followed by an i.v. injection of
5× 106 bone marrow cells from male Rgs1−/−ApoE−/− and ApoE−/−
mice.
2.2. Quantitative real time RT-PCR
Total RNA was isolated using RNeasy kits (Qiagen, UK) and reverse
transcribed to cDNA using SuperScript II Reverse Transcriptase
(Invitrogen, UK). Quantitative real-time PCR was performed with
10–50 ng of cDNA on an iCycler IQ real time detection system (Bio-Rad
Laboratories Ltd., UK). Gene expression was determined using TaqMan
Gene Expression Assays (Applied Biosystems, UK) relative to the level
of the house keeping genes β-actin for mouse, and GAPDH for human
using real time RT-PCR. Relative quantitation of gene expression was
performed using the comparative Ct method (ΔΔCt).
2.3. Primary cell isolation, culture and cell line transfections
Primary cells and whole thoracic aortas were obtained from 16-
week-old ApoE−/− and Rgs1−/−ApoE−/− mice. Primary endothelial
cells were isolated from PBS perfused lung tissue. Lungs were ﬁnely
minced and digested in an enzyme solution of DMEM containing
0.18 U/ml Liberase Blendzyme 3 (130 μl; Roche, UK) and 0.1mg/ml
DNase I (100 μl, Roche, UK) for 1 h at 37 °C with gentle agitation.
Puriﬁcation of endothelial cells was performed by magnetic cell sorting
(Miltenyi Biotec, UK) by positive selection using anti-CD31 microbeads
(Miltenyi Biotec, UK). Primary VSMCs were isolated by the aortic ex-
plant method. Aortas were cut into small segments following en-
dothelial cell denudation and adhered onto 2% gelatin coated wells and
cultured in DMEM complete growth media for 2 weeks. Outgrowing
VSMCs from explants of aortic tissue were harvested using Trypsin/
EDTA and pelleted for RNA.
The murine vascular aortic smooth muscle cell line, MOVAS (ATCC
CRL-2797) were transiently transfected at 50% conﬂuency with
plasmid expressing Myc-DDK (FLAG) tagged murine Rgs1 (Origene) or
an empty mammalian expression vector (pcDNA3.1) using FuGENE HD
(Roche) in serum free DMEM media. Transfections were performed at
3:1 ratio of FuGENE HD to 1 μg DNA. To check for transfection eﬃ-
ciency, in parallel experiments, intracellular staining and ﬂow cyto-
metry was performed for the FLAG tag using an anti-FLAG FITC anti-
body (Sigma). For staining of intracellular FLAG expression, cells were
washed, ﬁxed in 2% PFA (Life Technologies,) then permeabilised by
incubation with Cytoﬁx/Cytoperm then washed in PermWash (BD
Biosciences). Cells were then incubated in Fc block and antibody
stained for FLAG. Data were acquired using a CyAn Analyser ﬂow
cytometer (Beckman Coulter, UK) and then analysed using Summit
(Dako, UK) and FlowJo (Tree Star Inc., USA) software. Between 48 and
72 h, the time point at which the signalling assays were performed, 72%
of all cells were FLAG tag positive, indicating RGS1 expression in
transfected cells (Supplementary Fig. 1).
2.4. Measurement of pErk, pJNK and pp38 MAPK
MOVAS cells were seeded in 24-well plates and transfected with
pcDNA3.1 or Rgs1, 24 h prior to performance of assays. Transfected
cells were incubated in serum-free media 12 h prior to treatment of cells
with 1 uM of Angiotensin II over 30min. Cells were then lysed in
Sureﬁre lysis buﬀer, and AlphaScreen Sureﬁre pERK, pJNK, pp38, total
ERK and GAPDH assays (PerkinElmer, Beaconsﬁeld, UK) measuring
phosphorylated and total proteins were performed, as described [8].
The ﬂuorescence signal in both assays was measured using the PHER-
Astar FS microplate reader (BMG Labtech). The ratio of phosphorylated
ERK (pERK) to total ERK, pJNK and pp38 to GAPDH was measured at
each time point. All assay conditions were performed in four biological
replicates on two independent occasions.
2.5. Angiotensin II infusion and unconscious arterial pressure monitoring
16week old chimeric male mice were anaesthetized with isoﬂurane
by inhalation and osmotic mini pumps (Alza Corp, USA) delivering Ang
II (3mgkg−1 per day; Sigma-Aldrich) for 14 days were implanted
subcutaneously. At day 14, mean arterial blood pressure and heart rate
was measured by catheterizing the right common carotid artery with a
Millar 1.4 French blood pressure probe and transducer (Millar
Instruments Inc., Houston, TX) coupled to a Powerlab/4sp data acqui-
sition system (ADInstruments Pty Ltd., New Castle, Australia) and
passing the probe into the ascending aorta. After 15min equilibrium
period blood pressure was measured for 5min and the average re-
cordings for this time taken.
2.6. Isometric tension vasomotor studies
Vasomotor function was analysed using isometric tension studies in
a wire myograph (Multi-Myograph 610M, Danish Myo Technology,
Denmark). Brieﬂy, mice were culled by overdose of inhaled isoﬂurane
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and vascular rings were isolated from the thoracic aorta or mesenteric
arcades. The aortic rings or 2nd order mesenteric arteries (2 mm) were
mounted on a wire myograph containing 5ml of Krebs–Henseleit buﬀer
(KHB [in mmol/l]: NaCl 120, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2
2.5, NaHCO3 25, glucose 5.5) at 37 °C, gassed with 95% O2/5% CO2.
After allowing vessels to equilibrate for 30min, the optimal tension was
set (equivalent to 100mmHg). The vessel viability was tested using
60mM KCl. Concentration–response contraction curves were estab-
lished using cumulative half-log concentrations of phenylephrine,
U46619 and Ang II. Acetylcholine and SLIGRL were used to stimulate
endothelium-dependent vasodilatations in increasing cumulative con-
centrations. Responses were expressed as a percentage of the pre-con-
stricted tension. The NO donor sodium nitroprusside (SNP) was used to
test endothelium-independent smooth muscle relaxation in the pre-
sence of 100 μML-NAME. The MEK inhibitor, PD98059 (10 uM) and the
L-type voltage gated calcium channel antagonist, Nifedipine (50 nM)
were used to block PE induced vasoconstriction in aortas. All phar-
macological drugs were pre-incubated at least 20min before the do-
se–response curves were determined. All drugs used were purchased
from Sigma Aldrich.
2.7. Statistical analysis
Between group comparisons of normally distributed measurements
were assessed by Student's t-test. One-way AVOVA was used to compare
more than two data groups and Dunnett's post-test was used to compare
each group to a control (untreated) group. Two-way ANOVA was used
to compare multiple data groups aﬀected by two independent variables,
with a Bonferroni correction to compare groups with each other.
Diﬀerences were considered statistically signiﬁcant at P < 0.05.
3. Results
3.1. Rgs1 deﬁciency in non-haematopoietic cells results in Angiotensin II-
induced hypertension in ApoE−/− mice
We had previously shown that Ang II infusion for 14 days resulted in
a signiﬁcant increase in blood pressure in Rgs1−/−ApoE−/− mice. We
ﬁrst aimed to establish if the increase in blood pressure that was ob-
served at the slow pressor dose used previously, was still present at a
higher pressor dose of Ang II. Invasive blood pressure recordings in
unconscious mice were performed after 14 days of Ang II infusion
(3mg/kg/day). Consistent with our previous study [6], we found sig-
niﬁcant diﬀerences in systolic blood pressure between ApoE−/− mice
transplanted with ApoE−/− bone marrow and Rgs1−/−ApoE−/− mice
transplanted with Rgs1−/−ApoE−/− bone marrow
(101.3 ± 3.944mmHg versus 137.5 ± 3.056mmHg; P < 0.0001;
Fig. 1A). In addition an increase in systolic blood pressure was also
observed in Rgs1−/−ApoE−/− mice transplanted with ApoE−/− bone
marrow (101.3 ± 3.944mmHg versus 132.4 ± 5.218mmHg;
P=0.0002; Fig. 1A, D), indicating that the increase in systolic blood
pressure was not due to a contribution of haematopoietic cells as de-
scribed in previous studies [9]. In line with the changes observed in
systolic blood pressure, a signiﬁcant increase in diastolic blood pressure
between ApoE−/− mice transplanted with ApoE−/− bone marrow and
Rgs1−/−ApoE−/− mice transplanted with ApoE−/− bone marrow was
signiﬁcantly altered (65.18 ± 3.462mmHg versus
85.21 ± 2.652mmHg; Fig. 1B; P=0.0002). Heart rate was similar
between ApoE−/− and Rgs1−/−ApoE−/− mice (450.2 ± 25.29 beats/
min versus 470.2 ± 13.06 beats/min; Fig. 1C).
3.2. Rgs1 mRNA down-regulation in response to prolonged Ang II
stimulation
We next examined the possible regulation of Rgs1 to the eﬀects of
Ang II-mediated AT1 receptor activation in the vasculature. To assess
this we measured the expression of Rgs1 following the administration of
Ang II in vivo and in vitro. We ﬁrst measured the expression of Rgs1
mRNA in thoracic aortas from ApoE−/−mice implanted with saline and
Ang II for 5 days and found Rgs1 mRNA expression was signiﬁcantly
reduced in aortas from Ang II-treated ApoE−/−mice compared to saline
treated mice (Fig. 2A). We next measured expression in isolated and
cultured primary endothelial and VSMCs stimulated with Ang II in vitro
(Fig. 2B) and found Rgs1 expression was reduced with stimulation.
These ﬁndings indicate RGS1 is a likely candidate for negative regula-
tion of the Gαq proteins coupled to the Ang II type 1 receptor in the
vascular wall, and endothelial and VSMCs.
3.3. Rgs1 deletion leads to enhanced vasoconstriction in aortas and
mesenteric arteries from ApoE−/− mice
VSMCs express a number of GPCRs, such as adrenergic receptors
that are essential in mediating sympathetic signalling. Alpha-adrenergic
receptors are Gαq coupled and induce phospholipase C (PLC) activation
and a subsequent increase in intracellular calcium which is required for
the initiation of calcium dependant SMC contraction, and in vessels;
calcium dependant vasoconstriction.
To test the eﬀect of RGS1 in Gαq vasomotor function, we de-
termined vascular reactivity in conduit vessels from ApoE−/− and
Rgs1−/−ApoE−/− mice. No diﬀerence was detected between the con-
traction response to 60mmol∙L−1 KCl in ApoE−/−
(7.872 ± 0.59mNmm−1) and Rgs1−/−ApoE−/− aortas
(7.561 ± 0.30mNmm−1) (Fig. 3A). Receptor-mediated vasoconstric-
tions to α-adrenergic agonist, phenylephrine (PE), were signiﬁcantly
enhanced in Rgs1−/−ApoE−/− aortas compared to ApoE−/− controls
(Fig. 3B). In contrast to PE, receptor-mediated vasoconstrictions to AT1
agonist, Ang II had very little eﬀect on vasoconstrictions in aortas from
both ApoE−/− and Rgs1−/−ApoE−/− mice (Fig. 3C). Additionally,
endothelium-dependent vasodilatation was impaired in Rgs1−/
−ApoE−/− aortas compared to ApoE−/− control aortas (Fig. 3D), but
there was no diﬀerence in endothelium-independent vasodilatation to
SNP between the genotypes (Fig. 3E). To address the ﬁnding that the
enhanced contractile response to vasoconstrictors in Rgs1−/
−ApoE−/− aortas was in part due to MAPK signalling we assessed
vasoconstriction to PE in the presence of a MAPK/Erk (MEK) inhibitor
and found the response was blunted (Fig. 3F). Smooth muscle con-
traction is also dependent on calcium signalling, therefore we assessed
the response of Rgs1−/−ApoE−/− aortas to PE vasoconstriction in
the presence of a L-type voltage gated calcium channel antagonist. We
observed that the enhanced contractile response to PE in Rgs1−/
−ApoE−/− aortas was reduced by an L-type voltage gated calcium
channel antagonist to the same extent as that of ApoE−/− aortas
(Fig. 3G). These observations indicate that calcium signalling and
MAPK signalling are major eﬀectors of Rgs1-mediated vascular con-
tractile responses, which are known to be activated downstream of the
Gaq receptor signalling.
To further investigate the relationships between blood pressure and
changes in the resistance vasculature, mesenteric arteries from ApoE−/
− and Rgs1−/−ApoE−/− mice were isolated and the contractile re-
sponse to vasoconstrictors and vasodilators were determined. In Rgs1−/
−ApoE−/− mesenteric arteries, receptor-mediated vasoconstrictions to
thromboxane A2 receptor agonist, U46619, were signiﬁcantly enhanced
compared to ApoE−/− controls (Fig. 4A). In addition, receptor-medi-
ated vasoconstrictions to AT1 receptor agonist, Ang II were also
markedly enhanced in Rgs1−/−ApoE−/− compared to ApoE−/−
(Fig. 4B). Endothelium-dependent vasodilatations in response to ACh
and the proteinase-activated receptor 2 agonist, SLIGRL were both
signiﬁcantly impaired in Rgs1−/−ApoE−/− mesenteric arteries when
compared with that in ApoE−/− mesenteric arteries (Fig. 4C, D). The
vasodilatory response to ACh were normalised in the presence of non-
selective nitric oxide synthase inhibitor (L-NAME) and showed no
change between groups (Fig. 4E). Furthermore, endothelium-
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independent vasodilatation to SNP was enhanced in Rgs1−/−ApoE−/−
mesenteric arteries when compared to mesenteric arteries from ApoE−/
− mice (Fig. 4F), indicating the impairment of vasodilatation in Rgs1−/
−ApoE−/− mesenteric arteries was due to the alteration of vascular
smooth muscle sensitivity. Together, these ﬁndings indicate that Rgs1
regulates blood pressure in resistance arteries.
3.4. Rgs1 attenuates Ang II stimulated Erk1/2 phosphorylation in VSMCs
Ang II signals through AT1 receptors (AT1R), that are implicated in
AngII-induced vasoconstriction. Following activation of the receptor,
Gα and Gβγ subunits dissociate, activating downstream signalling
cascades. Extracellular regulated kinases 1 and 2 are ubiquitously uti-
lized proteins for examining vasoactive signalling due to their role in
the propagation of ligand activated signalling through GPCRs [10].
Speciﬁcally, this signalling has been connected to Gαq and Gαi sig-
nalling, and can lead to a number of intracellular downstream eﬀects
ranging from migration and adhesion to proliferation. ERK is phos-
phorylated and activated by at least three downstream AT1R signalling
pathways, including the protein kinase C (PKC)-dependent pathway,
the β-arrestin-dependent pathway, and the epidermal growth factor
receptor (EGFR) transactivation pathway [11]. To assess the role of
RGS1 in the Ang II-stimulated activation of the MAPK signalling
pathway, we assessed the levels of phosphorylated Erk1/2 protein and
other known kinases induced by Ang II, using transient transfections of
Rgs1 in the murine vascular smooth muscle cell line (MOVAS). We
found that RGS1 reduced pERK signalling following Angiotensin II sti-
mulation over a 30min time course (Fig. 5A), but not pJNK or pp38
signalling (Fig. 5B, C). Furthermore, we also found pERK levels at 10,
15 and 20min were below baseline. The mechanisms underlying the
increased contraction in Rgs1 deﬁcient vessels and Ang II-mediated
hypertension in Rgs1−/−ApoE−/− mice are likely to involve
diﬀerent signalling cascades involving both MAPK signalling and cal-
cium inﬂux, which are known to be activated downstream of the alpha-
adrenergic receptor and AT1R. Numerous signalling pathways in re-
sponse to Ang II are mediated by reactive oxygen species (ROS) and
oxidative stress underlies major vascular diseases including athero-
sclerosis and abdominal aortic aneurysm. Ang II-induced ROS including
superoxide and hydrogen peroxide, can inﬂuence vascular tone, re-
modelling and induce hypertension by vascular constriction, as well as
nitric oxide inactivation [12]. We assessed hydrogen peroxide released
from VSMC transfected with Rgs1, stimulated with Ang II for 12 h. We
observed no diﬀerences in basal hydrogen peroxide production, and
after Ang II stimulation in supernatants from VSMCs transfected with
Rgs1 (data not shown).
4. Discussion
The modulation of blood pressure by GPCRs is essential in the
maintenance of normal cardiovascular function, which when compro-
mised can result in vascular dysfunction and hypertension, a risk factor
for peripheral atherosclerosis, renal failure, myocardial infarction and
stroke. Furthermore, GPCR activity has been a target by many drugs to
treat hypertension, including AT1 receptor and β- adrenergic receptor
antagonists [13]. To date, three members of the RGS protein family;
RGS2, RGS4 and RGS5 have been linked to blood pressure maintenance
[1]. Our results provide new insights into the role of RGS1 as an ad-
ditional regulator of vascular tone and blood pressure. In this study we
have shown that loss of Rgs1 on the hyperlipidemic ApoE−/− back-
ground resulted in an enhanced arterial constrictor response in both
conduit and resistance arteries. In addition, the loss of Rgs1 resulted in
endothelial cell dysfunction with a blunted endothelial dilator response,
which was apparent despite an increase in VSMC sensitivity to NO.
Hypertension can be associated with the dysfunction of the renin
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Fig. 1. Rgs1−/−ApoE−/− chimeric mice have
increased blood pressure responses after Ang II in-
fusion for 14 days.
Chimeric ApoE−/− and Rgs1−/−ApoE−/− mice
were infused with Ang II (3mgkg−1 per day) over
14 days and blood pressure measured at day 14 in
anaesthetized mice using a Millar catheter. (A)
Systolic blood pressure (B) Diastolic blood pressure
(C) Heart rate in Rgs1−/−ApoE−/− and ApoE−/
− chimeric mice. (D) Representative traces of sys-
tolic blood pressure in chimeric mice using a Millar
catheter (***P < 0.001; n=10–11 animals per
group). WT=ApoE−/−; KO=Rgs1−/−ApoE−/
−.
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angiotensin system (RAS) [14]. Angiotensin II (Ang II), a primary ef-
fector of the RAS, is produced both systemically and locally in the vessel
wall [15] with its eﬀects mediated by the Angiotensin type I receptors.
We show that loss of Rgs1 leads to an increased sensitivity to chronic
treatment with Ang II resulting in a signiﬁcant increase in both systolic
and diastolic blood pressure. Previous studies have shown a role of
haematopoietic cells, speciﬁcally T cells in the hypertensive response to
Ang II [9]. Using the rag1−/− mice lacking T and B cells and adoptive
transfer, Guzik et al., demonstrated hypertension was associated with T-
cell inﬁltration in perivascular tissue, oxidative stress and impairment
in endothelial-dependent vasodilatation. As we and others have pre-
viously shown, RGS1 is highly expressed in leukocytes and plays a
critical role in myeloid cell [6] and lymphoid cell [16] retention in
inﬂammatory disease pathogenesis. Hence in order to ascertain if the
increased blood pressure response in Rgs1−/−ApoE−/− Ang II treated
mice was in part due to a contribution of RGS1 from leukocytes we
generated bone marrow chimeras. The increased blood pressure re-
sponse was only observed in Rgs1−/−ApoE−/− receiving Rgs1−/
−ApoE−/− or ApoE−/− bone marrow, strongly implicating loss of Rgs1
in the vessel wall, results in the enhanced hypertensive response to Ang
II. In our previous study, we examined the T-cell and B-cell phenotype
of Rgs1−/−ApoE−/− mice and found no signiﬁcant alterations, sug-
gesting RGS1 in lymphocytes in the context of atherosclerosis and Ang
II induced AAA has a less signiﬁcant role to that in myeloid cells in
vascular inﬂammation. We did not observe any diﬀerences in heart rate
between Rgs1−/−ApoE−/− mice and ApoE−/− mice despite the ob-
served increase in blood pressure. Previous studies have demonstrated
that Ang II modiﬁes the barrow receptor reﬂex either by decreasing
sensitivity, or by resetting the reﬂex to a higher value [17,18], and this
central eﬀect most likely explains the absence of reﬂex bradycardia.
Other RGS proteins have been implicated in the aetiology of hy-
pertension. There is strong evidence linking Rgs2 and hypertension in
humans. Genetic studies have identiﬁed Rgs2 single nucleotide poly-
morphisms (SNPs) in hypertension cohorts from several regions around
the world [19]. Rgs1 also resides in the same locus of chromosome 1q,
which harbours multiple susceptibility genes that aﬀect blood pressure
levels [20,21], indicating potential SNPs in Rgs1 could also aﬀect hy-
pertension in humans. Previous studies have shown that Rgs2−/− mice
are hypertensive at baseline and following Ang II infusion [22]. RGS2 is
required for cGMP-mediated inhibition of vasoconstrictor-triggered
Ca2+ signalling [23,24].
The loss of RGS1 resulted in a signiﬁcant increase in the contractile
response to phenylephrine in the aorta, and to Ang II and the throm-
boxane mimetic U46619 in resistance arteries. It is unlikely that the
enhanced constrictor response observed is due to an alteration in re-
modelling in these vessels as there was no diﬀerence in the contractile
response to KCL. The enhanced contraction to PE was blunted in both
Rgs1−/−ApoE−/− mice and ApoE−/− aortas following addition of
MEK inhibitor and an L-type voltage gated calcium channel antagonist.
Contraction is maintained by calcium sensitisation of the contractile
proteins via several signalling pathways. Phenylephrine, Ang II [25]
and U46619 [26] act via Gaq signalling to cause Ca2+ dependent
phosphorylation of MLC via activation of phospholipase C. In addition
these agonists also activate G12/13 signalling which increases calcium
sensitivity by Rho kinase-mediated inhibition of MLC phosphorylation.
Erk1/2 can potentiate contraction via caldesmon phosphorylation,
leading to separation from actin and thereby increasing the binding of
actin and myosin [27]. Rgs1 is an upstream eﬀector of many signalling
pathways including the MAPK pathway, acting at the level of the Ga
protein to cause signal termination. Previous in vitro studies have
shown that RGS1 is a Gai and Gαq GTPase-activating protein and a
potential G12 eﬀector antagonist [28]. It is likely that the enhanced
constrictor response observed in the aorta and mesenteric arteries of
Rgs1−/−ApoE−/− mice is due to loss of RGS1 inactivation of Gq and
G12/13 and loss of signal termination. Furthermore, receptor stimula-
tion by Ang II is followed by a rapid desensitization of the intracellular
signal transduction and a decrease in cell surface receptor number,
which could account for the drop in pErk1/2 levels from baseline fol-
lowing Ang II stimulation of VSMCs. In Rgs2−/− mice, the enhanced
constrictor response was due to loss of the NO mediated upregulation of
RGS2 activity, leading to an alteration in balance between the con-
strictor and dilator responses towards a constricted phenotype. It is
unlikely that a similar mechanism is responsible in our study, as in
contrast the Rgs2−/− mice, we observed an enhanced dilatory response
to the NO donor SNP. The absence of RGS1, eﬀects the regulation of
VSMC contraction and dilation in response to the agonists tested, but
does not rule out the possibility that RGS1 speciﬁcally regulates other
GPCR-mediated pathways that were not tested in this study. In contrast
to Rgs1 and Rgs2 deﬁcient mice being hypertensive, contradictory ob-
servations have been found in Rgs5−/− mice. Rgs5−/− mice have been
shown to be hypotensive [29] and hypertensive [30]. The mechanism
for hypotension is thought to occur through inhibition of NO-mediated
dilatory signalling. However, in arterial VSMCs, RGS5 inhibits Ang II
and Endothelin-1-induced intracellular Ca2+ transients mediated by
Gαi and Gαq signalling [31]. These contrasting roles imply that RGS
proteins function in a complex system of GPCR signal transduction by
their selectivity towards speciﬁc G-proteins. In line with the ﬁndings
observed for Rgs1 in this study, Rgs2 and Rgs5 mRNA transcripts are
also regulated by Ang II in VSMCs [32] and aortas from Ang II infused
mice [30], respectively. The in vivo Ang II infusion model indicated
Rgs1 provided negative feedback to Ang II signalling and provided the
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opportunity to investigate the prolonged Ang II treatment of endothelial
cells and VSMCs which showed down-regulation of Rgs1. Together,
these data suggest that Rgs1, Rgs2 and Rgs5 are functionally important
negative regulators of Ang II signalling in the vessel wall.
In addition to the alteration in the contractile response, a blunted
endothelial dependent dilator response was also observed in both aorta
and resistance mesenteric arteries from Rgs1−/−ApoE−/− mice. Both
ACh and the PAR-2 agonist SLIGRL act via Gq11 dependent endothelial
cell receptors. If RGS1 were coupled to these GPCRs then it would be
expected that loss of RGS1 would result in an enhanced dilator re-
sponse. In our study, a signiﬁcant proportion of the dilator response to
Ach was inhibited by NOS inhibition, indicating that the majority of the
dilatory response was due to NOS derived vasodilators. Previous in vivo
studies have shown that a slow pressor dose of Ang II is associated with
a signiﬁcant increase in oxidative stress [33]. The blunted dilatory re-
sponse observed in Rgs1−/−ApoE−/−mice could be due to chronic over
activation of the Ang II signalling pathway leading to increased reactive
oxygen species and decreased NO bioavailability. Although we did not
observed any diﬀerences in hydrogen peroxide production in VSMCs
stimulated with Ang II, this does not account for possible changes in
vascular tissue. Interestingly, in contrast to the blunted response to
dilation observed with Ach, the dilatory response to the PAR-2 agonist
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SLIGRL did not show a reduction in the maximum dilatory response but
instead a decreased sensitivity. This diﬀerence could be due to the re-
lative potency of these two compounds as SLIGRL has been shown to
induce a more potent dilatory response compared to Ach [34]. How-
ever, it could also be due to diﬀerences in the relative contribution of
vasodilators; SLIGRL has been shown to utilize both NOS-cGMP de-
pendent and independent mechanisms [35].
In conclusion, our results indicate that RGS1 regulates blood pres-
sure to a signiﬁcant extent to relax the resistance vasculature and at-
tenuate vasoconstrictor signalling in the vasculature. We propose that
RGS1 terminates Ang II signalling through accelerating the inactivation
of the Gaq subunit of AT1 receptors that can propagate signals via
multiple pathways including downstream Erk1/2 signalling pathways
and intracellular calcium levels, which results in attenuated VSMC
contraction. Furthermore, genetic impairment of Rgs1 therefore may
contribute to the development of hypertension. These ﬁndings further
promote the importance of RGS proteins as potential targets for the
treatment of hypertension. Speciﬁcally, pharmacological agents that
up-regulate RGS1 expression or activity in the vessel wall may augment
the action of vasodilatory agonists and provide a novel means of
treating hypertension.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.vph.2018.04.002.
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Fig. 5. Rgs1 reduces Ang II activation of pErk1/2 signalling in VSMCs.
(A) Rgs1 transfected VSMCs have reduced pErk1/2 activation following 1 μM
Ang II stimulation over 30min but not (B) pJNK and (C) pp38 activation
(**P < 0.01; n= 4 technical replicates, 2 independent experiments).
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